- Home
- TALO vs DNTH Comparison
TALO vs DNTH Comparison
Compare TALO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | DNTH |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TALO | DNTH |
|---|---|---|
| Price | $11.02 | $43.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $14.30 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 2.2M | 703.2K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,872,554,000.00 | $3,078,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $6.23 | $13.37 |
| 52 Week High | $12.20 | $45.46 |
Technical Indicators
Market Signals| Indicator | TALO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 57.17 |
| Support Level | $10.64 | $42.02 |
| Resistance Level | $11.39 | $44.00 |
| Average True Range (ATR) | 0.37 | 1.77 |
| MACD | -0.11 | -0.24 |
| Stochastic Oscillator | 24.44 | 60.83 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.